Dr. Muhunthan Thillai
Dr. Muhunthan Thillai | |
|---|---|
 | |
| Born | |
| Nationality | British |
| Citizenship | United Kingdom |
| Occupation | |
| Organization |
|
| Website | |
Dr. Muhunthan Thillai is a British physician, researcher, entrepreneur, and author, specializing in respiratory and general medicine, with a particular focus on sarcoidosis and lung fibrosis.[1] Dr. Thillai is a consultant chest physician at Royal Papworth and Addenbrooke's hospitals. He is the co-founder and CEO of Qureight, a medical technology company leveraging AI to advance the understanding and treatment of complex diseases.[2]
Dr. Thillai is also an associate professor at the University of East Anglia. He has co-authored five books and numerous research papers on lung diseases such as hypersensitivity pneumonitis, idiopathic pulmonary fibrosis (IPF), and sarcoidosis.[3]
Early life and education
Thillai was born in Sri Lanka and grew up in Jersey, Channel Islands. Both of his parents were doctors who immigrated to the United Kingdom in the 1980s.
Thillai completed his undergraduate education in 1999 with a BA in Medical Journalism from the University of Westminster. He earned his MBBS degree from Imperial College London in 2002 and became a member of the Royal College of Physicians (MRCP) in 2005. He pursued a PhD in immunology and proteomics at Imperial College London, completing it in 2012. Additionally, he received a Certificate of Completion of Training (CCT) in Respiratory and General Medicine in 2015.
Career
Thillai began his medical training as a junior doctor in London and Oxford. He was the Infectious Diseases Fellow for the Map of Medicine project at NHS Connecting for Health and served as Editor-in-Chief of Junior Dr magazine. He received a Research Training Fellowship from the Wellcome Trust.[4]
His clinical training included specializations in lung cancer, pulmonary vascular disorders, and lung transplantation. Thillai is a consultant chest physician at Royal Papworth and Addenbrooke's hospitals. He also serves as co-chair of the 2020 British Thoracic Society guidelines for sarcoidosis.[5]
In August 2020, Thillai co-founded Qureight, a medical technology company based in Cambridge. Qureight specializes in data curation using advanced AI to explore new trial endpoints for complex diseases such as idiopathic pulmonary fibrosis, lung cancer, and pulmonary hypertension. The company's platform assists in structuring image and biomarker data from biopharmaceutical and healthcare institutions. Its clients include pharmaceutical companies such as Roche, Galapagos, and Takeda. Recently, Qureight secured £1.5 million in seed funding led by Playfair Capital.[6]
Dr. Thillai is also a medical researcher, having authored several research papers on sarcoidosis. He has co-authored five books and several book chapters. Dr. Thillai has also presented at various international scientific conferences.[7]
Bibliography
- Clinical Handbook of Interstitial Lung Disease (2019)
- Clinical Tuberculosis: A Practical Handbook (2015).
- Pocket Tutor Understanding ABGs & Lung Function Tests (2010).
- Royal Society of Medicine Career Handbook: ST3-Senior Doctor (2012)
- Royal Society of Medicine Career Handbook: FY1-ST2 (2011).
- Getting the Most from Your ST1-3 Years (2012).
Published works
- Thillai M, Wickremasinghe M, Lalvani A, Moller D, Mitchell D. "Aeitiology of Sarcoidosis." In Sarcoidosis, edited by Mitchell D, Wells AU, Spiro S, Moller D. Hodder Arnold, 2012.
- Thillai M, Lalvani A, Mitchell D. "The Kveim Test in Sarcoidosis." In Sarcoidosis, edited by Mitchell D, Wells AU, Spiro S, Moller D. Hodder Arnold, 2012.
- Moller D, Thillai M, Lalvani A, Mitchell D. "Immunology of Sarcoidosis." In Sarcoidosis, edited by Mitchell D, Wells AU, Spiro S, Moller D. Hodder Arnold, 2012.
- Thillai M. "Respiratory Tract Diseases." In Intellectual Disability and Ill Health, edited by O'Hara J, McCarthy J, Bouras N. Cambridge University Press, 2010.
- Lalvani A, Thillai M. "Diagnosis of Latent Tuberculosis: A 100-Year Update." In Horizons in Medicine, edited by Mathieson P. Royal College of Physicians, 2008.
- Thillai M, Pollock K, Pareek M, Lalvani A. "Interferon Gamma Release Assays for TB, Current and Future Applications." Expert Review of Respiratory Medicine, 2014.
- Thillai M, Powrie D. "Quality Improvement in Respiratory Medicine: Designing and Implementing a Bronchoscopy Checklist." BMJ Quality Improvement Reports, 2013.
- Thillai M, Eberhardt C, Lewin AM, Potiphar L, Hingley-Wilson S, Sridhar S, et al. "Sarcoidosis and Tuberculosis Cytokine Profiles: Indistinguishable in Bronchoalveolar Lavage but Different in Blood." PLoS One, 2012.
- Thillai M, Potiphar L, Eberhardt C, Pareek M, Dhawan R, Kon OM, et al. "Obstructive Lung Function in Sarcoidosis May Be Missed, Especially in Older White Patients." European Respiratory Journal, 2012.
- Lalvani A, Thillai M. "Diagnosis of Tuberculosis: Principles and Practice of Using Interferon-Gamma Release Assays." Breathe, 2009.
References
- ↑ "Muhunthan Thillai". Asian in Tech. Retrieved 27 June 2024.
- ↑ Smith, Chris (27 September 2023). ""8 Questions with Playfair" ft. Muhunthan Thillai @ Qureight". Playfair Blog. Retrieved 27 June 2024.
- ↑ "Used - Like New, CLINICAL Handbook OF INTERSTITIAL LUNG DISEASE (Paperback, Muhunthan Thillai, David R.Moller, Keith C. Meyer)". www.flipkart.com. Retrieved 27 June 2024.
- ↑ "Qureight founder: Pitching to investors is energising once you take the plunge". UKTN. 12 January 2024. Retrieved 27 June 2024.
- ↑ "Cambridge data company Qureight raises £1.5m seed funding to speed up clinical trials". Cambridge Independent. 3 February 2022. Retrieved 27 June 2024.
- ↑ Coney, Philippa (25 April 2022). "Venturing forth: Qureight – integrating data with AI to solve complex diseases - News & insight". Cambridge Judge Business School. Retrieved 27 June 2024.
- ↑ "Books by Muhunthan Thillai (Author of Understanding ABGs & Lung Function Tests (Pocket Tutor)-INTERNATIONAL EDITION)". www.goodreads.com. Retrieved 27 June 2024.